CPPD 治疗：选择和证据。
Therapy for CPPD: Options and Evidence.
机构信息
Sección de Reumatología, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Hospital General Universitario de Alicante, Pintor Baeza 12, 03010, Alicante, Spain.
Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain.
出版信息
Curr Rheumatol Rep. 2018 Apr 19;20(6):31. doi: 10.1007/s11926-018-0739-z.
PURPOSE OF REVIEW
Current evidence and accumulated experience for the management of calcium pyrophosphate deposition disease (CPPD) are presented.
RECENT FINDINGS
Contrary to other rheumatic inflammatory conditions that account for high interest and growing research, advances in treating CPPD are still very limited and mostly derive from those achieved in gout. Once formed, calcium pyrophosphate crystals cannot be dissolved; therefore, management relies on the control of crystal-derived inflammation. Besides classical agents-such as colchicine, glucocorticoids, or NSAIDs-the use of targeted therapies, mostly against interleukin-1, has provided a relevant relief for refractory CPPD patients in recent years. Meanwhile, former enthusiasm about conventional disease-modifying agents such as methotrexate is currently controversial.
目的综述
目前对焦磷酸钙沉积病（CPPD）的管理提出了相关证据和积累的经验。
最新发现
与其他风湿炎症性疾病相比，CPPD 引起了广泛关注并取得了大量研究进展，但在治疗方面进展仍然非常有限，且大多源自痛风领域的进展。焦磷酸钙晶体一旦形成，就无法溶解；因此，治疗依赖于控制晶体引起的炎症。除了秋水仙碱、糖皮质激素或 NSAIDs 等经典药物外，近年来针对白细胞介素-1 的靶向治疗为 CPPD 难治性患者提供了显著缓解。同时，人们对甲氨蝶呤等传统疾病修饰剂的热情目前也存在争议。
Zotero 插件